Titan bestrides Phase III opioid dependency data, plans NDA meeting with FDA in autumn
This article was originally published in Scrip
Executive Summary
Titan Pharmaceuticals says it hopes to meet with the US FDA this autumn to review the development programme of and plan an NDA filing for its investigational drug, Probuphine (buprenorphine in an ethylene-vinyl acetate rod), for the treatment of opioid addiction.